ClinicalTrials.gg
Not yet recruitingNCT07797829Updated Sep 3, 2026

Buccal Mucosal Graft Ureteroplasty for Treatment of Proximal Ureteric Strictures, A Clinical Case Series.

An Early Phase 1 interventional study of Buccal mucosal graft ureteroplasty in Ureter Stricture, sponsored by Mohamed Salah Abdul Mawgoud. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Mohamed Salah Abdul Mawgoud · Early Phase 1, Interventional, and Treatment

Phase
Early Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

While short strictures and even long strictures in the distal or mid-section of the ureter can easily be repaired by end-to-end anastomosis or simple re-implantation as well as standard procedures, such as psoas bladder hitch and/or Boari-flap, reconstructions of long proximal ureter remain rare and challenging (1), Although long segment proximal ureteric stricture (LPUS) have traditionally been managed with ileal ureter replacement (IUR) or renal auto transplantation (RA), these procedures may be technically difficult to perform and associated with considerable morbidity.(2) While buccal mucosa grafts (BMG) in urethral reconstruction are well established, only few small series for BMG in ureteric stricture have been reported. While showing promising results, these studies were flawed by inhomogeneous cohorts of patients with different kinds of strictures like uretero-pelvic junction (UPJ) obstruction, proximal and mid-ureter strictures that were treated with different techniques such as onlay ureteroplasty or augmented end-to-endanastomosis. Even though buccal mucosa harvesting is well established and straightforward current guidelines still do not recommend BMG ureteroplasty as an equal alternative to more invasive alternatives such as ileum interposition or renal auto-transplantation. (3) In 1999, Naude (4) introduced an alternative and innovative technique for treating ureteric strictures by utilizing buccal mucosa grafts (BMG) in conjunction with omental wrapping. Implementing onlay BMG during ureteral reconstruction eliminates the necessity for extensive ureterolysis, reducing disruption to the peri-ureteral blood supply. Furthermore, the BMG can be customized to accommodate the dimensions of the ureteral defect, ensuring a tension-free anastomosis. (5)

02

Conditions studied

  • Ureter Stricture
03

In context

Constriction, Pathologic

456 studies on the registry are indexed under Constriction, Pathologic; 109 are open to participants now.

This study's planned enrollment of 25 is below the median of 72 across 295 interventional studies indexed under Constriction, Pathologic.

Browse Constriction, Pathologic studies →

Lead sponsor

This is the only study on the registry with Mohamed Salah Abdul Mawgoud as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (age ≥ 18 years) of either sex.
  • Confirmed diagnosis of long (>2 cm) upper and middle ureteric strictures, either fresh or recurrent with previous open or endoscopic intervention.

Exclusion criteria

Exclusion Criteria:

  • Malignant ureteric stricture or stricture secondary to active pelvic/retroperitoneal .
  • Active urinary tract infection at the time of planned surgery.
  • Uncorrected coagulopathy or other to anesthesia/surgery.
  • Active oral mucosal disease, oral submucous fibrosis or previous bilateral grafting.
  • Solitary non-functioning kidney on the affected side with differential renal function\<15% on renogram (relative or absolute non-functioning renal unit) unless reconstruction is otherwise indicated.
  • Pregnancy.
  • Cases of ureteric avulsion where ileal ureter substitution will be used or cases with complete ureter obliteration no passing guidewire or ureteric catheter.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Patients with proximal ureteric strictures

    Procedure: Buccal mucosal graft ureteroplasty

Interventions

  • ProcedureBuccal mucosal graft ureteroplasty

    Ureteric Exposure and Stricturoplasty The affected ureteric segment is approached (open flank) for upper third and Abernathy for middle ureteric stricture. and the stricture is identified and confirmed. The ureter is opened longitudinally (ureterotomy) with no. 11 blade across the full length of the stricture guided by the catheter onto 1 cm of healthy tissue proximally and distally. In short tight areas with maximal narrowing \<1 cm, mucosa is excised and mucosa to mucosa anastomosis is done. The prepared BMG is fashioned onto the ureterotomy defect (onlay technique) or configured as an augmentation patch and secured with vicryl 5-0 continuous absorbable sutures over a silicon 6/26 Dj stent. A double-J ureteric stent is placed across the repaired segment prior to completion of the graft inset to splint the reconstruction and ensure adequate drainage during graft take. Omental wrap or peri-ureteric fat/tissue coverage of the graft is performed where feasible to enhance graft vasculariza

06

What researchers measure

Primary outcomes

  1. Surgical success defined as ureteric patency without need for re-intervention

    Time frame: 1 year

  2. Surgical success defined as ureteric patency without need for re- intervention

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Nasef AS, Tagrida IAE, Salman MF, Elatreisy A, Khaled SM. Buccal mucosal graft for onlay ureteroplasty in the management of proximal ureteral stricture. Single centre, prospective trial. Arch Ital Urol Androl. 2025 Jun 30;97(2):13695. doi: 10.4081/aiua.2025.13695. Epub 2025 May 15. PubMed 40372200 ↗
  • Naude JH. Buccal mucosal grafts in the treatment of ureteric lesions. BJU Int. 1999 May;83(7):751-4. doi: 10.1046/j.1464-410x.1999.00019.x. PubMed 10368190 ↗
  • Kocot A, Kalogirou C, Vergho D, Riedmiller H. Long-term results of ileal ureteric replacement: a 25-year single-centre experience. BJU Int. 2017 Aug;120(2):273-279. doi: 10.1111/bju.13825. Epub 2017 Mar 21. PubMed 28220579 ↗
  • Lee M, Lee Z, Koster H, Jun M, Asghar AM, Lee R, Strauss D, Patel N, Kim D, Komaravolu S, Drain A, Metro MJ, Zhao L, Stifelman M, Eun DD; Collaborative of Reconstructive Robotic Ureteral Surgery (CORRUS). Intermediate-term outcomes after robotic ureteral reconstruction for long-segment (>/=4 centimeters) strictures in the proximal ureter: A multi-institutional experience. Investig Clin Urol. 2021 Jan;62(1):65-71. doi: 10.4111/icu.20200298. Epub 2020 Nov 12. PubMed 33258325 ↗
  • Hefermehl LJ, Tritschler S, Kretschmer A, Beck V, Stief CG, Schlenker B, Strittmatter F. Open ureteroplasty with buccal mucosa graft for long proximal strictures: A good option for a rare problem. Investig Clin Urol. 2020 May;61(3):316-322. doi: 10.4111/icu.2020.61.3.316. Epub 2020 Mar 9. PubMed 32377609 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07797829
Lead sponsor
Mohamed Salah Abdul Mawgoud
Responsible party
Mohamed Salah Abdul Mawgoud (Assistant lecturer, Assiut University) — Sponsor-investigator
First posted
Sep 1, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Mar 15, 2027 (estimated)
Completion
Mar 15, 2028 (estimated)
Last update
Sep 3, 2026

Study contacts

Mohamed AbdelMawgoud, Assistant lecturer
Contact
mo.salah@aun.edu.eg
+201011486957

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion